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The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil 
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Gender   N.S. 
Male 7 (53.8%) 3 (42.9%)  
Female 6 (46.2%) 4 (57.1%)  
Age 71.1 8.1 75.0 4.0 N.S. 
Location   N.S. 
Right 7 (53.8%) 2 (28.6%)  
Left 2 (15.4%) 2 (28.6%)  
Rectum 4 (30.8%) 3 (42.8%)  
Histological grade   N.S. 
Well 1 (7.7%) 1 (14.3%)  
Moderate 12 (92.3%) 5 (71.4%)  
Poor 0 (0%) 1 (14.3%)  
Invasion depth   N.S. 
T2 1 (7.7%) 0 (0%)  
T3 12 (92.3%) 6 (85.7%)  
T4 0 (0%) 1 (14.3%)  
Lymphatic metastasis   N.S. 
Positive 7 (53.8%) 5 (71.4%)  
Negative 6 (46.2%) 2 (28.6%)  
Lymphatic invasion   N.S. 
Positive 13 (100%) 5 (71.4%)  
Negative 0 (0%) 2 (28.6%)  
Venous invasion   N.S. 
Positive 8 (61.5%) 3 (42.8%)  
Negative 5 (38.5%) 4 (57.1%)  
Stage (UICC, 2009)   N.S. 
IIA 3 (23.1%) 0 (0%)  
IIB 3 (23.1%) 2 (28.6%)  
IIIA 1 (7.7%) 0 (0%)  
IIIB 2 (15.4%) 3 (42.8%)  
IIIC 4 (30.8%) 2 (28.6%)  
1 5-FU
RNA PCR 
lysis buffer RLT Buffer (QIAGEN) 
 (QIAGEN) MM300 (QIAGEN) 
RNA RNeasy Mini kit (QIAGEN) 
RNA 260 nm
RNA RNA cDNA
PrimeScript® RT Master Mix (Perfect Real Time) (TaKaRa) 
cDNA QuantiTect SYBR Green PCR kit (QIAGEN) 
LightCycler software ver 3.5 (Roche Applied Science) PCR 
95 , 15 95 , 10
60 , 30 50
c-MYC : 5’-CACCAGCAGCGACTCTGA-3’; 5’-GATCCAGACTCTGACCTTTTGC-3’,  
ABCB5 : 5’-CACAAAAGGCCATTCAGGCT-3’, 5’-GCTGAGGAATCCACCCAATCT-3’,  
GAPDH : 5’-TTGGTATCGTGGAAGGACTCA-3’, 5’-TGTCATCATATTTGGCAGGTT-3’  
GAPDH c-MYC 2– CT [14]
5-FU
Caco-2, COLO-320, COLO205, LoVo
FBS 10%
RPMI1640 COLO-320; COLO205, F-12 LoVo, MEM Caco-2 37 , 5% 
CO2 5-FU Caco-2 Caco-2 5-FU (2 M) 
MEM (10% FBS) 12
Small interfering RNA (siRNA) 
c-MYC siRNA scrambled siRNA Thermo Scientific
ABCB5 siRNA Life Technologies siRNA
[15] COLO-320
c-MYC
c-MYC pcDNA3  (pcDNA3-c-MYC) Addgene
pcDNA3
Lipofectamine 2000 (Life Technologies) 
COLO205
Nuclear Complex Co-IP Kit (Active Motif) 
COLO205, COLO-320
1% NP-40 lysis buffer (50mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 1x 
Protease Inhibitor Cocktail) [16]
COLO-320, Caco-2 5-FU Caco-2
RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1x Protease Inhibitor Cocktail) 
 (QIAGEN) MM300 (QIAGEN) 
10% 
SDS-PAGE (sodium dodecyl sulfate poly acrylamide gel electrophoresis) SDS
PVDF
0.3% 1
c-MYC  1:1000, Santa Cruz 
Biotechnology ABCB5  1:1000, ProSci Inc.
MRP5  1:1000, Abcam
BCRP/ABCG2  1:1000, Abcam PARP1
 1:1000, Santa Cruz Biotechnology -Tubulin
 1:1000, Santa Cruz Biotechnology 4
2
 1:5000, Dako
ECL Prime Western Blotting Detection Reagent (GE Healthcare) 
Image J
5-FU
96 1 6 103 FBS
10% 37 , 5% CO2 48
5-FU 1 M, 5 M, 10 M 48
Cell Count Reagent SF (Nacalai Tesque) 37 90
450nm
RT-PCR 
RNA cDNA PCR [15]
50 , 30 94 , 2 94 , 30
54.5  (ABCB5), 55  (GAPDH), 57.5  (c-MYC), 60  (MDR1, 
MRP1, ABCC4, ABCC5), 30 72 , 30 20





ChIP-ITTM Express Enzymatic (Active motif) 
c-MYC  (Santa Cruz Biotechnology) IgG (Santa 
Cruz Biotechnology) DNA 
ABCB5 c-MYC
PCR 94 , 20





7 BALB / c
1 106 Caco-2  (BD Biosciences) 
1000 mm3 4
 DMSO  ( )  5-FU
 (10 mg/kg)  10058-F4  (20 mg/kg)  5-FU (10 mg/kg) + 10058-F4 (20 
mg/kg) 2 0, 3, 5, 7, 10, 14
14
Animal
Care and Use committee
10  (Wako) 
24 10 , 20 , 30% 6




IgG (H + L) Alexa Fluor 555 F (ab’)2 fragment (Life Technologies) 
IgG-TR (Santa Cruz Biotechnology) 1 DAPI
BZ-X710 All-in-One  (KEYENCE) 360 ± 20 nm
545 ± 12.5 nm
TUNEL
4 m
K 37 , 30 0.1% Triton X-100 PBS 2 TUNEL
In situ Cell Death Detection Kit (Roche Applied Science) 
DAPI BZ-X710 All-in-One 
 (KEYENCE) 360 ± 20 nm 545 ± 12.5 nm
SPSS for Windows Ver. II
 ± 2 Student’s t



















B. c-MYC c-MYC 5-FU
Kaplan-Meier
c-MYC expression 






Gender   N.S. 
Male 7 (63.6%) 3 (33.3%)  
Female 4 (36.4%) 6 (66.7%)  
Age 70.8 8.7 74.3 3.7 N.S. 
Location   N.S. 
Right 6 (54.5%) 3 (33.3%)  
Left 1 (9.1%) 3 (33.3%)  
Rectum 4 (36.4%) 3 (33.3%)  
Histological grade   N.S. 
Well 1 (9.1%) 1 (11.1%)  
Moderate 10 (90.9%) 7 (77.8%)  
Poor 0 (0%) 1 (11.1%)  
Invasion depth   N.S. 
T2 0 (0%) 1 (11.1%)  
T3 11 (100%) 7 (77.8%)  
T4 0 (0%) 1 (11.1%)  
Lymphatic metastasis   N.S. 
Positive 6 (54.5%) 6 (66.7%)  
Negative 5 (45.5%) 3 (33.3%)  
Lymphatic invasion   N.S. 
Positive 11 (100%) 7 (77.8%)  
Negative 0 (0%) 2 (22.2%)  
Venous invasion   N.S. 
Positive 7 (63.6%) 4 (44.4%)  
Negative 4 (36.4%) 5 (55.6%)  
Stage (UICC, 2009)   N.S. 
IIA 2 (18.2%) 1 (11.1%)  
IIB 3 (27.3%) 2 (22.2%)  
IIIA 1 (9.1%) 0 (0%)  
IIIB 2 (18.2%) 3 (33.3%)  
IIIC 
Chemotherapy regimen 























c-MYC COLO205 COLO205 pcDNA3
pcDNA3-c-MYC
c-MYC 2A c-MYC
COLO205 5-FU 2B c-MYC
c-MYC COLO-320 COLO-320




2. 5-FU c-MYC c-MYC




B. pc-DNA3 pc-DNA3-c-MYC COLO205 DMSO
5-FU (1, 2, 5, 10 M) 48 WST-8
5-FU DMSO
* p < 0.05 ** p < 0.01
C. Scrambled siRNA c-MYC siRNA COLO-320
c-MYC PARP1
PARP1 c-MYC scrambled siRNA
COLO-320
D. Scrambled siRNA c-MYC siRNA COLO-320 DMSO
5-FU (1, 2, 5, 10 M) 48 WST-8
5-FU DMSO
* p < 0.05 ** p < 0.01
c-MYC ABCB5
COLO-320 c-MYC siRNA c-MYC 5-FU
ABC 5  (ABCB5, MDR1, 
MRP1, ABCC4, ABCC5 [17-23]) mRNA RT-PCR
c-MYC ABCB5, ABCC4, ABCC5 3A
c-MYC ABCB5 ABCB5
ABCB5 c-MYC
ABCB5  (-5000 bp
+1500 bp) 4  (-3415 bp/-3410 bp, -1812 bp/-1807 bp, -87 bp/-82 bp, +1101 
bp/+1106 bp) c-MYC  (CATGTG) 3B c-MYC
 (CACGTG CACGCG) 
ABCB5 2  (-3415 bp/-3410 bp, -87 bp/-82 bp) 
c-MYC c-MYC 3C ABCB5
c-MYC
3. ABCB5 c-MYC ABCB5
A. Scrambled siRNA c-MYC siRNA COLO-320 total RNA






C. c-MYC COLO-320 ChIP
3B c-MYC, 






DMSO 10058-F4 48 COLO-320
 (ChIP) ABCB5 c-MYC
c-MYC 4A RT-PCR
mRNA 10058-F4 ABCB5
4B, C 5-FU ABC ABCC5, ABCG2 
[26] 10058-F4 10058-F4 ABCC5
COLO-320 ABCC5 4D
ABCG2 COLO-320 10058-F4 ABCG2
4D c-MYC ABCB5
c-MYC ABCB5
4. ABCB5 c-MYC 10058-F4




c-MYC, c-MYC ; IgG, IgG; 
INPUT, ChIP 1/100 DNA
B. DMSO 10058-F4 (32, 64, 100 M) 48 COLO-320
total RNA RT-PCR ABCB5 GAPDH
GAPDH ABCB5 DMSO
COLO-320
C. DMSO 10058-F4 (64 M) 48 COLO-320 whole 
cell lysates ABCB5, -Tubulin
-Tubulin ABCB5 DMSO
COLO-320
D. DMSO 10058-F4 (64 M) 48 COLO-320 whole 











ABCB5 5-FU 5C, D
ABCB5 5-FU
5. ABCB5 5-FU
A. Scrambled siRNA ABCB5 siRNA COLO-320 whole cell 
lysates ABCB5, -Tubulin
-Tubulin ABCB5 scrambled 
siRNA COLO-320
B. Scrambled siRNA ABCB5 siRNA COLO-320 DMSO, 5-FU 
(5 M), 0.9% , cisplatin (5 M) 48 WST-8
5-FU DMSO
0.9% * p < 0.05
C. Caco-2 5-FU Caco-2 whole cell lysates ABCB5, 
-Tubulin
-Tubulin ABCB5 Caco-2
D. Caco-2 5-FU Caco-2 DMSO 5-FU (5 M) 72
WST-8




5-FU + 10058-F4 5-FU 10058-F4
5-FU + 10058-F4
6A, B
Ki67 TUNEL 5-FU 10058-F4 5-FU + 10058-F4
Ki67 6C, D TUNEL
6E, F ABCB5
5-FU ABCB5 10058-F4 5-FU 
+ 10058-F4 6G, H
6. 5-FU 10058-F4
Caco-2 1000 mm3
DMSO, 5-FU (10 mg/kg), 10058-F4 (20 mg/kg), 5-FU (10 mg/kg) + 10058-F4 (20 
mg/kg) 2
A. 14
B. 3, 5, 7, 10, 14
1000 mm3 * p < 0.05
C. 14
Ki67, DAPI Merge 40
50 m
D. 8 DAPI Ki67
* p < 0.05
E. 14
TUNEL, DAPI Merge 40
50 m
F. 8 DAPI TUNEL
* p < 0.05
G. 14
ABCB5, DAPI Merge 10
40 50 m
H. 14 whole 


























 (data not shown) ABCG2
COLO-320 10058-F4 ABCG2
ABCB5 COLO-320 5-FU
5-FU Caco-2 Caco-2 ABCB5
5-FU
c-MYC ABCB5 5-FU
5-FU + 10058-F4 5-FU 10058-F4
5-FU + 10058-F4 Ki67
TUNEL In vitro 5-FU + 
10058-F4 Annexin V PI PCNA
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